Gemcitabine news

All news on Gemcitabine (also known as Gemzar): plants, production capacities, investments and involved companies.

23 March 2026

Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma

Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
16 January 2026

Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL

Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.
8 December 2025

Roche's Columvi Combo Shows Sustained Survival Benefit in Phase III Study

Columvi with GemOx doubles survival in R/R DLBCL patients, approved in 50+ countries, offering a non-transplant treatment option.
5 December 2025

Johnson & Johnson's INLEXZO™ Shows 74% One-Year Disease-Free Survival in High-Risk NMIBC

New data shows high survival rates and bladder preservation in BCG-unresponsive NMIBC patients using gemcitabine intravesical system, with minimal severe side effects.
20 October 2025

Johnson & Johnson's INLEXZO™ and Cetrelimab Show Promising Pre-Surgical Results in Bladder Cancer

Phase 2b study shows INLEXZO™ plus cetrelimab achieves significant pathologic response rates in muscle invasive bladder cancer patients ineligible for platinum-based chemotherapy.

Who will be producing Gemcitabine in the future?

Find out with chemXplore Alpha

Learn more